A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life.
Yeung YA, Wu X, Reyes AE 2nd, Vernes JM, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, Damico LA, Ferrara N, Lowman HB.
Yeung YA, et al. Among authors: lien s.
Cancer Res. 2010 Apr 15;70(8):3269-77. doi: 10.1158/0008-5472.CAN-09-4580. Epub 2010 Mar 30.
Cancer Res. 2010.
PMID: 20354184